Bruker Responds to U.S. District Court Ruling on GeoMx Digital Spatial Profiler Products
A Significant Development in the Patent Infringement Case
Bruker (BRKR) has issued a statement regarding the U.S. District Court for the District of Delaware’s ruling on the patent infringement case involving its NanoString (NSTG) business and 10x Genomics. The court’s decision upholds the jury’s damages award of approximately $31.6 million plus interest and a damages true-up for GeoMx sales since the November 2023 verdict.
Key Takeaways from the Ruling
The court declined 10x Genomics’ request for enhanced damages and attorneys’ fees, but granted an injunction against GeoMx products in the United States. However, the proposed injunction includes a carve-out for sales of consumables to the installed base of GeoMx customers existing as of the November 2023 verdict. This allows them to complete their ongoing research.
Impact on Bruker’s Business
The ruling does not affect the CosMx or nCounter product lines, which Bruker acquired from NanoString in its asset purchase transaction of May 2024. Notably, GeoMx instrument revenue represents less than 0.2% of Bruker’s total revenue.
Bruker’s Response to the Ruling
Todd Garland, President of the Bruker Spatial Biology division, expressed disagreement with the court’s decision to grant an injunction with respect to sales of GeoMx products to new customers in the United States. Bruker plans to promptly seek a stay of any injunction that is finally ordered and looks forward to the appeal of its case being heard by the U.S. Court of Appeals for the Federal Circuit.
A Commitment to the Scientific Community
Bruker remains dedicated to ensuring that the scientific community has the freedom to select the best spatial biology platforms to advance their research. The company believes that the patents licensed by 10x and asserted against it are invalid and describe a fundamentally different method than what is used by the GeoMx system.
Leave a Reply